A recombinant protein containing highly conserved hemagglutinin residues 81-122 of influenza H5N1 induces strong humoral and mucosal immune responses

BioScience Trends

Volumn 7, Issue 3, 2013, Pages 129-137

  Li, Ye ^a,b   Du, Lanying ^b   Qiu, Hongjie ^c   Zhao, Guangyu ^c   Wang, Lili ^b   Zhou, Yusen ^c   Jiang, Shibo ^b,d   Gao, Jimin ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b NEW YORK BLOOD CENTER   (United States)

^c BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^d FUDAN UNIVERSITY   (China)

Author keywords

Conserved sequences; H5N1 vaccine; Hemagglutinin; Influenza; Mucosal responses

Indexed keywords

HEMAGGLUTININ; RECOMBINANT PROTEIN;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CHEMISTRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETICS; HUMAN; HUMORAL IMMUNITY; IMMUNOLOGY; INFLUENZA VIRUS A H5N1; MALE; MOUSE; MUCOSAL IMMUNITY;

ANIMALS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMAGGLUTININS; HUMANS; IMMUNITY, HUMORAL; IMMUNITY, MUCOSAL; INFLUENZA A VIRUS, H5N1 SUBTYPE; MALE; MICE; MICE, INBRED BALB C; RECOMBINANT PROTEINS;

EID: 84880641719     PISSN: 18817815     EISSN: 18817823     Source Type: Journal    
DOI: 10.5582/bst.2013.v7.3.129     Document Type: Article

References (42)

1. Gao R, Cao B, Hu Y, et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med. 2013; 68:1888-1897.
2. Pappaioanou M. Highly pathogenic H5N1 avian influenza virus: Cause of the next pandemic? Comp Immunol Microbiol Infect Dis. 2009; 32:287-300.
3. Hunter P. H5N1 infects the biosecurity debate. Governments and life scientists are waking up to the problem of dual-use research. EMBO Rep. 2012; 13:604-607.
4. Peiris JS, de Jong MD, Guan Y. Avian influenza virus (H5N1): A threat to human health. Clin Microbiol Rev. 2007; 20:243-267.
5. Du L, Leung VH, Zhang X, et al. A recombinant vaccine of H5N1 HA1 fused with foldon and human IgG Fc induced complete cross-clade protection against divergent H5N1 viruses. PLoS One. 2011; 6:e16555.
6. Moon HJ, Lee JS, Talactac MR, Chowdhury MY, Kim JH, Park ME, Choi YK, Sung MH, Kim CJ. Mucosal immunization with recombinant influenza hemagglutinin protein and poly gamma-glutamate/chitosan nanoparticles induces protection against highly pathogenic influenza A virus. Vet Microbiol. 2012; 160:277-289.
7. Wang TT, Tan GS, Hai R, Pica N, Ngai L, Ekiert DC, Wilson IA, Garcia-Sastre A, Moran TM, Palese P. Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc Natl Acad Sci U S A. 2010; 107:18979-18984.
8. Verma S, Dimitrova M, Munjal A, Fontana J, Crevar CJ, Carter DM, Ross TM, Khurana S, Golding H. Oligomeric recombinant H5 HA1 vaccine produced in bacteria protects ferrets from homologous and heterologous wild-type H5N1 influenza challenge and controls viral loads better than subunit H5N1 vaccine by eliciting high-affinity antibodies. J Virol. 2012; 86:12283-12293.
9. Du L, Jin L, Zhao G, Sun S, Li J, Yu H, Li Y, Zheng BJ, Liddington RC, Zhou Y, Jiang S. Identification and structural characterization of a broadly neutralizing antibody targeting a novel conserved epitope on the influenza virus H5N1 hemagglutinin. J Virol. 2013; 87:2215-2225.
10. Du L, Zhao G, Sun S, Zhang X, Zhou X, Guo Y, Li Y, Zhou Y, Jiang S. A critical HA1 neutralizing domain of H5N1 influenza in an optimal conformation induces strong cross-protection. PLoS One. 2013; 8:e53568.
11. Golde WT, Gollobin P, Rodriguez LL. A rapid, simple, and humane method for submandibular bleeding of mice using a lancet. Lab Anim (NY). 2005; 34:39-43.
12. Nayak B, Kumar S, DiNapoli JM, Paldurai A, Perez DR, Collins PL, Samal SK. Contributions of the avian influenza virus HA, NA, and M2 surface proteins to the induction of neutralizing antibodies and protective immunity. J Virol. 2010; 84:2408-2420.
13. Wei CJ, Xu L, Kong WP, Shi W, Canis K, Stevens J, Yang ZY, Dell A, Haslam SM, Wilson IA, Nabel GJ. Comparative efficacy of neutralizing antibodies elicited by recombinant hemagglutinin proteins from avian H5N1 influenza virus. J Virol. 2008; 82:6200-6208.
14. Patel A, Tran K, Gray M, Li Y, Ao Z, Yao X, Kobasa D, Kobinger GP. Evaluation of conserved and variable influenza antigens for immunization against different isolates of H5N1 viruses. Vaccine. 2009; 27:3083-3089.
15. Kreijtz JH, Suezer Y, de MG, van den Brand JM, van AG, Schnierle BS, Kuiken T, Fouchier RA, Lower J, Osterhaus AD, Sutter G, Rimmelzwaan GF. Preclinical evaluation of a modified vaccinia virus Ankara (MVA)-based vaccine against influenza A/H5N1 viruses. Vaccine. 2009; 27:6296-6299.
16. Prabakaran M, Madhan S, Prabhu N, Qiang J, Kwang J. Gastrointestinal delivery of baculovirus displaying influenza virus hemagglutinin protects mice against heterologous H5N1 infection. J Virol. 2010; 84:3201-3209.
17. Shoji Y, Bi H, Musiychuk K, et al. Plant-derived hemagglutinin protects ferrets against challenge infection with the A/Indonesia/05/05 strain of avian influenza. Vaccine. 2009; 27:1087-1092.
18. Schwartz JA, Buonocore L, Suguitan A, Jr., Hunter M, Marx PA, Subbarao K, Rose JK. Vesicular stomatitis virus-based H5N1 avian influenza vaccines induce potent cross-clade neutralizing antibodies in rhesus macaques. J Virol. 2011; 85:4602-4605.
19. Schwarz TF, Horacek T, Knuf M, Damman HG, Roman F, Drame M, Gillard P, Jilg W. Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults. Vaccine. 2009; 27:6284-6290.
20. Leroux-Roels I, Roman F, Forgus S, Maes C, De BF, Drame M, Gillard P, van der Most R, Van MM, Hanon E, Leroux-Roels G. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: An open non-randomised extension of a double-blind randomised primary study. Vaccine. 2010; 28:849-857.
21. Lakey DL, Treanor JJ, Betts RF, Smith GE, Thompson J, Sannella E, Reed G, Wilkinson BE, Wright PF. Recombinant baculovirus influenza A hemagglutinin vaccines are well tolerated and immunogenic in healthy adults. J Infect Dis. 1996; 174:838-841.
22. Treanor JJ, Schiff GM, Couch RB, Cate TR, Brady RC, Hay CM, Wolff M, She D, Cox MM. Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults. J Infect Dis. 2006; 193:1223-1228.
23. Tonegawa K, Nobusawa E, Nakajima K, Kato T, Kutsuna T, Kuroda K, Shibata T, Harada Y, Nakamura A, Itoh M. Analysis of epitope recognition of antibodies induced by DNA immunization against hemagglutinin protein of influenza A virus. Vaccine. 2003; 21:3118-3125.
24. Du L, Zhou Y, Jiang S. Research and development of universal influenza vaccines. Microbes Infect. 2010; 12:280-286.
25. Loureiro S, Ren J, Phapugrangkul P, Colaco CA, Bailey CR, Shelton H, Molesti E, Temperton NJ, Barclay WS, Jones IM. Adjuvant-free immunization with hemagglutinin-Fc fusion proteins as an approach to influenza vaccines. J Virol. 2011; 85:3010-3014.
26. Garcia JM, Pepin S, Lagarde N, Ma ES, Vogel FR, Chan KH, Chiu SS, Peiris JS. Heterosubtype neutralizing responses to influenza A (H5N1) viruses are mediated by antibodies to virus haemagglutinin. PLoS One. 2009; 4:e7918.
27. Weldon WC, Wang BZ, Martin MP, Koutsonanos DG, Skountzou I, Compans RW. Enhanced immunogenicity of stabilized trimeric soluble influenza hemagglutinin. PLoS One. 2010; 5:e12466.
28. He Y, Lu H, Siddiqui P, Zhou Y, Jiang S. Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies. J Immunol. 2005; 174:4908-4915.
29. Chen H, Xu X, Jones IM. Immunogenicity of the outer domain of a HIV-1 clade C gp120. Retrovirology. 2007; 4:33.
30. Martyn JC, Cardin AJ, Wines BD, Cendron A, Li S, Mackenzie J, Powell M, Gowans EJ. Surface display of IgG Fc on baculovirus vectors enhances binding to antigen-presenting cells and cell lines expressing Fc receptors. Arch Virol. 2009; 154:1129-1138.
31. Du C, Wang M, Liu J, Pan M, Cai Y, Yao J. Improvement of thermostability of recombinant collagen-like protein by incorporating a foldon sequence. Appl Microbiol Biotechnol. 2008; 79:195-202.
32. Pakkanen O, Hamalainen ER, Kivirikko KI, Myllyharju J. Assembly of stable human type I and III collagen molecules from hydroxylated recombinant chains in the yeast Pichia pastoris. Effect of an engineered C-terminal oligomerization domain foldon. J Biol Chem. 2003; 278:32478-32483.
33. Letarov AV, Londer YY, Boudko SP, Mesyanzhinov VV. The carboxy-terminal domain initiates trimerization of bacteriophage T4 fibritin. Biochemistry (Mosc). 1999; 64:817-823.
34. Boudko SP, Londer YY, Letarov AV, Sernova NV, Engel J, Mesyanzhinov VV. Domain organization, folding and stability of bacteriophage T4 fibritin, a segmented coiled-coil protein. Eur J Biochem. 2002; 269:833-841.
35. Price GE, Soboleski MR, Lo CY, Misplon JA, Quirion MR, Houser KV, Pearce MB, Pappas C, Tumpey TM, Epstein SL. Single-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 viruses. PLoS One. 2010; 5:e13162.
36. Cerutti A, Cols M, Gentile M, Cassis L, Barra CM, He B, Puga I, Chen K. Regulation of mucosal IgA responses: Lessons from primary immunodeficiencies. Ann N Y Acad Sci. 2011; 1238:132-144.
37. Brandtzaeg P. Induction of secretory immunity and memory at mucosal surfaces. Vaccine. 2007; 25:5467-5484.
38. Brandtzaeg P. Role of secretory antibodies in the defence against infections. Int J Med Microbiol. 2003; 293:3-15.
39. de Haan A, Haijema BJ, Voorn P, Meijerhof T, van Roosmalen ML, Leenhouts K. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration. Vaccine. 2012; 30:4884-4891.
40. Ichinohe T, Ainai A, Tashiro M, Sata T, Hasegawa H. PolyI: PolyC12U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants. Vaccine. 2009; 27:6276-6279.
41. Kreijtz JH, Osterhaus AD, Rimmelzwaan GF. Vaccination strategies and vaccine formulations for epidemic and pandemic influenza control. Hum Vaccin. 2009; 5:126-135.
42. Gosselin EJ, Bitsaktsis C, Li Y, Iglesias BV. Fc receptor-targeted mucosal vaccination as a novel strategy for the generation of enhanced immunity against mucosal and non-mucosal pathogens. Arch Immunol Ther Exp (Warsz). 2009; 57:311-323.